ANZCTR search results

The PROSPECT-OA study is a national registry that will track patients with osteoarthritis who receive radiotherapy as part of their standard clinical care. Osteoarthritis is a common condition that causes joint pain and stiffness, and radiotherapy is sometimes used to help manage symptoms. This registry aims to collect real-world information about treatment patterns, pain levels, and patient outcomes across GenesisCare sites in Australia. We hypothesise that radiotherapy can provide meaningful pain relief and improve quality of life for patients with osteoarthritis. By collecting data on pain scores and pain response, the study will help clinicians better understand how radiotherapy is used in practice and its impact on patients over time. Participants will be followed for up to 24 weeks after each course of radiotherapy, with pain response assessed at 12 weekly regular intervals.

This study aims to track adult and child (aged 5-17 years) participants who are using Medigrowth medicinal cannabis products for any chronic medical condition over a 12-month period. Who is it for? You may be eligible if you are an adult who is 18 years or older, seeking treatment for a refractory chronic medical condition at Azure Health, and considered suitable for medicinal cannabis by an Azure Health clinician. You must consent to being prescribed products supplied by Medigrowth Australia as per standard clinical practice (via the SAS or AP pathways), be able to read and understand English to complete study questionnaires, and provide informed consent. Alternatively, you may be eligible if you are a parent or guardian of a child aged 5–17 years who is seeking treatment for a refractory chronic medical condition at Azure Health and is considered suitable for medicinal cannabis by an Azure Health clinician. You must consent to your child being prescribed products supplied by Medigrowth Australia as per standard clinical practice (via the SAS or AP pathways), be able to read and understand English and assist your child to complete study questionnaires, and provide informed consent on behalf of your child. Study details Study participants will complete online questionnaires prior to starting their Medigrowth medicinal cannabis products (baseline), and then at 1 month, 3 months, 6 months, 9 months, and 12 months after entering the study. Questionnaires will assess patient-reported changes in mental health, pain, sleep, quality of life, global impression of change, and work performance using validated questionnaires. The study will also collect information on demographics, medical history, other therapies, and track how Medigrowth products are being used over time, including an estimate of CBD/THC dosages. The findings of this study are expected to inform clinicians about the safety and efficacy of Medigrowth medicinal cannabis products, and the outcomes may be used to inform future randomised controlled trials for specific indications.

This study aims to find out whether 3D-printed soft foods can improve the eating experience and nutritional intake of older adults living in aged care homes. Many residents require texture-modified foods because of swallowing difficulties, but these meals often look unappealing and may lead to poor appetite. We will compare a 3D-printed, easy-to-eat appetizer with the standard pureed appetizer currently used in aged care. Each participant will receive both types of foods at different times during the study. We hypothesise that older adults will enjoy the 3D-printed foods more, eat a greater amount of the meal, and have a more positive mealtime experience compared with standard pureed foods.

This study aims to adapt a specific Tai Chi program for a regional Australian community to determine if it is a feasible and helpful way to manage symptoms of fatigue, sleep disturbance, and depression in breast cancer survivors. Who is it for? You may be eligible for this study if you are a female aged 18 or older, completed chemotherapy for Stage 1, 2, or 3 breast cancer within the last three years and are currently experiencing moderate levels of tiredness, sleep problems, and low mood. Study details: Participants will attend a weekly, one-hour Tai Chi class (the "Easy 8 Form Yang Style") for a total of 8 weeks. All participants in this study will receive the Tai Chi training. Participants will complete assessments to monitor their symptoms at the start of the study, at the end of the 8-week program, and again four weeks later. It is hoped this research will determine if this Tai Chi program is an acceptable and effective therapy to help improve the well-being and symptom recovery of Australian breast cancer survivors.

Low-calorie sweeteners (LCS) have been widely used in food and beverages in recent decades. However, a recent World Health Organisation (WHO) report highlighted that people who consume LCS regularly have an increased risk of developing type 2 diabetes (T2D). Acesulfame potassium (Ace-K) is a widely used low-calorie sweetener that is absorbed from the gut and excreted in the urine. We want to find out whether Ace-K consumption reduces the amount of glucose excreted in the urine in pre-diabetes humans.

The study will compare blood levels of vardenafil between SDS089, a new nasal spray and tablets. In Part A each participant will receive a single dose of SDS089 2.5 mg, SDS089 5 mg and vardenafil tablet 20 mg with a 3-day washout period between dosing. In Part B each participant will receive a daily dose of SDS089 5 mg for five days. Participants will be confined in the clinical trial unit for the duration of the study (15 days).

Indigenous South Australians carry a disproportionate burden of dental diseases, with approximately 80 percent of Indigenous adults having both periodontal disease and dental caries. Poor oral health has profound impacts on both quality of life and social and emotional wellbeing. The chronic inflammatory nature of many dental conditions (for example, periodontal disease) mean there are widespread systemic impacts, including type 2 diabetes, chronic kidney disease and cardiovascular disease. Evidence suggests there are barriers experienced by Indigenous South Australians in accessing timely and culturally safe dental care. This application seeks to address these concerns by: (a) eliciting the views of Indigenous South Australians regarding their perspectives of what comprises culturally safe dental care, (b) providing such dental care and, (c) ascertaining the improvements in both oral and general health following receipt of timely, comprehensive and culturally safe dental care, with point-of-care testing used to assess changes in general health biomarkers following the dental intervention.

Polycystic Ovary Syndrome (PCOS) is a common but complex condition that is often delayed or difficult to diagnose. This study aims to understand how General Practitioners (GPs) in the Metropolitan Brisbane South and Logan regions currently diagnose and manage PCOS. The primary purpose is to assess GPs' knowledge of the latest 2023 International Guidelines, their current clinical practices, and the barriers they face, such as lack of time, software issues, or confidence when diagnosing the condition . Hypothesis: The study predicts that GPs who are aware of the 2023 International Guidelines will be more likely to use the recommended "simplified" diagnostic pathway (which avoids unnecessary ultrasound scans for certain patients) compared to those who are unaware of the guidelines. Method: Eligible GPs will be invited to complete an anonymous 15-minute online survey. The results will be used to develop better educational resources and support tools to help doctors diagnose PCOS more effectively.

This study aims to test a new automated device that delivers antibiotics gradually before surgery. The device, called IRIS, gives multiple smaller doses over 30 minutes, rather than one large dose, to reduce the risk of severe allergic reactions. We hypothesize that IRIS will both lower the chance of serious allergic events and still ensure patients receive enough antibiotic protection before surgery starts. By checking how easy IRIS is to use and whether it can safely administer the entire dose on time, we hope to show it can improve patient safety. If successful, this approach could make pre-operative antibiotic administration safer and more reliable in the future.

A new guideline was introduced in participating sites to exclude pulmonary embolism (PE) without the need for advanced imaging studies (computerised tomography pulmonary angiography or ventilation perfusion scans). This guideline involved accepting a higher threshold of a particular blood test (D-dimer) to rule out PE. Patients were contacted after 90 days post presentation to ask if they had been diagnosed with a PE or a deep vein thrombosis (which gives arise to PE).